MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
BeiGene, Ltd. Gross Profit 2011-2026 | BGNE
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit BeiGene, Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.22 B | 2.08 B | 1.13 B | 1.01 B | - | -570 M | -509 M | -35.6 M | -97 M | -49.4 M | -8.83 M | -2.32 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.22 B | -570 M | 560 M |
Quarterly Gross Profit BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.22 B | 1.15 B | 952 M | - | 831 M | 791 M | 627 M | - | 685 M | 499 M | 366 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 B | 366 M | 791 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M |  Canada |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
374 M | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Brickell Biotech
BBI
|
1.82 K | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
19.7 M | $ 2.97 | 3.12 % | $ 908 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
319 M | $ 215.29 | 4.59 % | $ 5 B |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
500 | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
-1.24 M | - | 0.59 % | $ 63 K | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
147 K | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
CASI Pharmaceuticals
CASI
|
17.6 M | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Celldex Therapeutics
CLDX
|
5.48 M | $ 25.15 | -1.95 % | $ 1.62 M | USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
Catalyst Biosciences
CBIO
|
109 M | $ 14.01 | 3.7 % | $ 922 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
12.4 B | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
87.5 M | $ 23.32 | 2.71 % | $ 2.76 B | USA |